<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744170</url>
  </required_header>
  <id_info>
    <org_study_id>O2-Demand-Study</org_study_id>
    <nct_id>NCT02744170</nct_id>
  </id_info>
  <brief_title>Effects of Supplemental Oxygen Delivery Via Demand Versus Continuous Flow in Hypoxemic COPD Patients</brief_title>
  <official_title>Effects of Supplemental Oxygen Delivery Via Demand Versus Continuous Flow in Hypoxemic COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schön Klinik Berchtesgadener Land</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schön Klinik Berchtesgadener Land</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxygen supplementation has been proven to be effective in hypoxemic COPD patients by&#xD;
      increasing oxygenation and reducing dyspnea. In clinical practice there are three common&#xD;
      oxygen delivery systems used: continuous oxygen flow (CF), demand oxygen delivery with liquid&#xD;
      oxygen (DDL) and demand oxgen delivery with portable oxygen concentrator (DDC). The CF&#xD;
      involves considerable wastage of oxygen because oxygen is supplied during in- and exhalation.&#xD;
      Demand oxygen delivery saves oxygen and results in a comparable oxygen saturation at rest in&#xD;
      COPD patients. However, it is unknown, if oxygen supplementation via demand oxygen delivery&#xD;
      is also sufficient during exercise in hypoxemic COPD patients. In addition, it has to be&#xD;
      considered that the lower weight of demand oxygen delivery system might enable patients for&#xD;
      higher physical activity level and mobility in daily life.&#xD;
&#xD;
      The effects of These three oxygen delivery systems shall be investigated by a randomized,&#xD;
      controlled cross-over Trial. Every patient has to perform an Incremental Shuttle Walk Test&#xD;
      and three Endurance Shuttle Walk Tests with three different oxygen supplementation (via CF,&#xD;
      DDL or DDK) in randomized order.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Principal Investigator will inform each patient about procedure, content and measurements&#xD;
      of the study. It is obligatory that each patient participating in the study gives a written&#xD;
      informed consent.&#xD;
&#xD;
      Following an initial incremental shuttle walk test (ISWT) in order to determine the&#xD;
      individual maximum capacity, patients will perform three endurance shuttle walk tests (ESWT)&#xD;
      at 85% of the maximal pace. In randomized order, patients will complete one ESWT on CF, one&#xD;
      on DDL (liquid oxygen) and one on DDC (portable oxygen concentrator). The time between the&#xD;
      three ESWTs will be 24 hours in order to give enough time for regeneration. All patients will&#xD;
      use the same oxygen devices (CF: Companion 1000 (CE 0050), Chart Industries, Inc. Garfield&#xD;
      Heights, Ohio, USA; DD [liquid oxygen]: Caire Spirit 300 (CE 0029), Chart Industries, Inc.&#xD;
      Garfield Heights, Ohio, USA), DD [portable concentrator]: Inogen G2, California, USA) and&#xD;
      will carry the oxygen device in a backpack. Continuous oxygen flow in liter per minute will&#xD;
      be compared to the level of demand delivery (e.g.: 2 l/min CF will be compared to DD level&#xD;
      2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen saturation at isotime of the endurance shuttle walk test (ESWT), compared between CF (liquid oxygen) and DD (liquid oxygen)</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>continuous transcutaneous recording during ESWT by Sentec-Digital-Monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breathing frequency</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>measured by Visionox</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory capacity</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>measured by Spiropalm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>continuous transcutaneous recording during ESWT by Sentec-Digital-Monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance during ESWT</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>total distance walked during ESWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>assessed by modified Borg scale (0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial pressure of carbon dioxide</measure>
    <time_frame>at baseline, at isotime of ESWT and at the end (maximal 20 min) of ESWT</time_frame>
    <description>continuous transcutaneous recording during ESWT by Sentec-Digital-Monitor</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 1, 2, 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 2,3, 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 3, 2, 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 1, 3, 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 2, 1, 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 3, 1, 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1 continuous flow oxygen supplementation</intervention_name>
    <description>This oxygen Supplementation is used in special order</description>
    <arm_group_label>COPD patients with delivery order 1, 2, 3</arm_group_label>
    <arm_group_label>COPD patients with delivery order 1, 3, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2, 1, 3</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2,3, 1</arm_group_label>
    <arm_group_label>COPD patients with delivery order 3, 1, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 3, 2, 1</arm_group_label>
    <other_name>Companion 1000 Chart Industries, Inc. Garfield Heights, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2 demand delivery liquid oxygen supplementation</intervention_name>
    <description>This oxygen Supplementation is used in special order</description>
    <arm_group_label>COPD patients with delivery order 1, 2, 3</arm_group_label>
    <arm_group_label>COPD patients with delivery order 1, 3, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2, 1, 3</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2,3, 1</arm_group_label>
    <arm_group_label>COPD patients with delivery order 3, 1, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 3, 2, 1</arm_group_label>
    <other_name>Caire Spirit 300 Chart Industries, Inc. Garfield Heights</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3 demand delivery oxygen supplementation via concentrator</intervention_name>
    <description>This oxygen Supplementation is used in special order</description>
    <arm_group_label>COPD patients with delivery order 1, 2, 3</arm_group_label>
    <arm_group_label>COPD patients with delivery order 1, 3, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2, 1, 3</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2,3, 1</arm_group_label>
    <arm_group_label>COPD patients with delivery order 3, 1, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 3, 2, 1</arm_group_label>
    <other_name>one oxygen concentrator, Inogen, Goleta, CA, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD patients (GOLD stage III to IV) with hypoxemia at rest or during exercise&#xD;
             (paO2&lt;60mmHg)&#xD;
&#xD;
          -  Participation in an inpatient pulmonary rehabilitation program (Schön Klinik BGL)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General exclusion criteria for exercise tests, e.g. acute coronary syndrome, acute&#xD;
             myo- or pericarditis, acute lung embolism, pulmonary infarction, acute uncontrolled&#xD;
             heart insufficiency&#xD;
&#xD;
          -  Signs of acute exacerbation&#xD;
&#xD;
          -  Any orthopedic or neurological disabilities that prevent patient from walking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Kenn, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philipps University Marburg Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Berchtesgadener Land</name>
      <address>
        <city>Schönau</city>
        <state>Berchtesgardener Land</state>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Schön Klinik Berchtesgadener Land</investigator_affiliation>
    <investigator_full_name>Klaus Kenn</investigator_full_name>
    <investigator_title>Prof. Dr. Klaus Kenn</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Incremental Shuttle Walk Test</keyword>
  <keyword>Endurance Shuttle Walk Test</keyword>
  <keyword>oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

